Computational identification of HCV neutralizing antibodies with a common HCDR3 disulfide bond motif in the antibody repertoires of infected individuals.
Nina G Bozhanova, Andrew I Flyak, Benjamin P Brown, Stormy E Ruiz, Jordan Salas, Semi Rho, Robin G Bombardi, Luke Myers, Cinque Soto, Justin R Bailey and 3 more
Review in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
6 citing papers in PubMed, 7 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors at 4 institutions in 2 countries.
Nina G BozhanovaDepartment of Chemistry, Vanderbilt University, Nashville, TN, 37235, USA.ORCID 0000-0002-2164-5698
Andrew I FlyakDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, 91125, USA.
Benjamin P BrownDepartment of Chemistry, Vanderbilt University, Nashville, TN, 37235, USA.
Stormy E RuizDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, 91125, USA.ORCID 0000-0003-0892-9626
Jordan SalasDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Semi RhoDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, 91125, USA.
Robin G BombardiVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.
Luke MyersVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.ORCID 0000-0003-1132-2550
Cinque SotoVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.
Justin R BaileyDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
James E CroweVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, 37232, USA.ORCID 0000-0002-0049-1079
Pamela J BjorkmanDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, 91125, USA.ORCID 0000-0002-2277-3990
Jens MeilerDepartment of Chemistry, Vanderbilt University, Nashville, TN, 37235, USA. jens@meilerlab.org.ORCID 0000-0001-8945-193X
California Institute of Technology · USVanderbilt University Medical Center · USVanderbilt University · USJohns Hopkins University · US
Funding
X-ray Absorption Spectroscopy (XAS) pp.711-759P41GM103393 · NIGMS · STANFORD UNIVERSITY · PI HODGSON, KEITH O · 2012 to 2019
$30.6M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007347 · NIGMS · VANDERBILT UNIVERSITY · PI WILLIAMS, CHRISTOPHER S. · 1985 to 2023
$26.3M
The development and pre-clinical assessment of novel HCV vaccines to generate T and B cell immunityU19AI159822 · NIAID · JOHNS HOPKINS UNIVERSITY · PI COX, ANDREA L · 2021 to 2025
$14.4M
Molecular and structural characterization of broadly neutralizing anti-HCV antibodiesR01AI127469 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Justin Richard Bailey · 2017 to 2026
$6.8M
Structure based design of trimer interface epitope focused universal influenza vaccinesU01AI150739 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CROWE, JAMES E · 2020 to 2024
$6.1M
Medical Scientist Training ProgramT32GM152284 · NIGMS · VANDERBILT UNIVERSITY · PI Christopher S. Williams · 2024 to 2026
$4.8M
Epitope-Based Design and Modified RNA Platform for Bivalent Marburgvirus VaccineR01AI141661 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI BUKREYEV, ALEXANDER, CROWE, JAMES E · 2019 to 2023
$3.9M
Immunization strategies to elicit broadly neutralizing antibodies against HCVR00AI153465 · NIAID · CORNELL UNIVERSITY · PI FLYAK, ANDREW I · 2022 to 2023
$498k
Development of a single-cell antibody cloning protocol for isolation of hepatitis C virus-specific broadly neutralizing antibodiesR21AI151353 · NIAID · JOHNS HOPKINS UNIVERSITY · PI BAILEY, JUSTIN RICHARD · 2020 to 2021
$450k
Immunization strategies to elicit broadly neutralizing antibodies against HCVK99AI153465 · NIAID · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI FLYAK, ANDREW I · 2020 to 2021
Despite recent success in hepatitis C virus (HCV) treatment using antivirals, an HCV vaccine is still needed to prevent reinfections in treated patients, to avert the emergence of drug-resistant strains, and to provide protection for people with no access to the antiviral therapeutics. The early production of broadly neutralizing antibodies (bNAbs) associates with HCV clearance. Several potent bNAbs bind a conserved HCV glycoprotein E2 epitope using an unusual heavy chain complementarity determining region 3 (HCDR3) containing an intra-loop disulfide bond. Isolation of additional structurally-homologous bNAbs would facilitate the recognition of key determinants of such bNAbs and guide rational vaccine design. Here we report the identification of new antibodies containing an HCDR3 disulfide bond motif using computational screening with the Rosetta software. Using the newly-discovered and already-known members of this antibody family, we review the required HCDR3 amino acid composition and propose determinants for the bent versus straight HCDR3 loop conformation observed in these antibodies.
Indexed as
Hepatitis CVaccinesAntibodies, NeutralizingBroadly Neutralizing AntibodiesComplementarity Determining RegionsDisulfidesHepacivirusHepatitis C AntibodiesHumansViral Envelope ProteinsAntibodies, NeutralizingBroadly Neutralizing AntibodiesComplementarity Determining RegionsDisulfidesHepatitis C AntibodiesVaccinesViral Envelope Proteins
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Computational identification of HCV neutralizing antibodies with a common HCDR3 disulfide bond motif in the antibody repertoires of infected individuals. · full record | OpenQuestion